Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 7/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839676 | 0.83 | ALDH1A1 (0.51) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL2711462 | 0.79 | ESR1 (0.59) | LMNAMAPT | |
| SCHEMBL30828709 | 0.79 | IDO1 (0.50) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL481909 | 0.79 | IDO1 (0.50) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL12646518 | 0.79 | FAAH (0.49) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL29793168 | 0.79 | FAAH (0.49) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL2710560 | 0.79 | PIM1 (0.41) | FAAHALDH1A1KMT2ALMNAAHR | |
| SCHEMBL5513632 | 0.79 | FAAH (0.49) | FAAHALDH1A1KMT2ALMNAGPR55 | |
| SCHEMBL4499993 | 0.79 | MAPT (0.54) | FAAHLMNAKDM4EMAPT | |
| SCHEMBL5049374 | 0.79 | HTR3A (0.40) | FAAHALDH1A1HTR3ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864290-B1 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LTD (IE) | 2017-06-14 | — | — | EP | disclosed |
| US-9422309-B2 | 3-O-heteroaryl-ingenol | LEO LABORATORIES LIMITED (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20150175622-A1 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LIMITED (IE) | 2015-06-25 | — | — | US | disclosed |
| EP-2864290-A2 | 3-O-HETEROARYL-INGENOL | Leo Laboratories Limited (IE) | 2015-04-29 | — | — | EP | disclosed |
| WO-2014001215-A2 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LIMITED (IE) | 2014-01-03 | — | — | WO | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5643923-A | TREATMENT OF ANXIETY, COGNITION ACTIVATORS, SENILITY OR ALZHEIMER'S | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| US-5578627-A | FOR TREATING CEREBRAL CIRCULATORY DISORDER, HEAD INJURY SEQUELAE AND/OR EPILEPSY | TOYAMA CHEMICAL CO., LTD. (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0665226-A1 | NOVEL 1,2-BENZISOXAZOLE DERIVATIVE OR SALT THEREOF, AND BRAIN PROTECTIVE AGENT COMPRISING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0456519-B1 | Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1994-07-13 | — | — | EP | disclosed |
| EP-0456519-A1 | Piperidyloxy- and quinuclidinyloxy- isoxazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175622-A1 | 3-O-HETEROARYL-INGENOL | VDR, RXRA, PPARG | FAAH 1549/4885ALDH1A1 275/4885KMT2A 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.